While disruption of CD40-CD40L in patients with homozygous mutations is associated with immunodeficiency, heterozygous carriers are unaffected, indicating that therapeutic inhibition of CD40-CD40L may be well-tolerated (68). Here, CD40 is linked to immunodeficiency disease.